Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Paromomycin
 | |
| Enghraifft o: | math o endid cemegol  |
|---|---|
| Math | (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R)-5-{[(1R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol |
| Màs | 615.296 uned Dalton |
| Fformiwla gemegol | C₂₃h₄₅n₅o₁₄ |
| Enw WHO | Paromomycin |
| Clefydau i'w trin | Cryptosporidiosis, amebiasis |
| Beichiogrwydd | Categori beichiogrwydd unol daleithiau america n |
| Rhan o | paromomycin metabolic process, paromomycin catabolic process, paromomycin biosynthetic process |
| Gwneuthurwr | Pfizer |
 Ffeiliau perthnasol ar Gomin Wicimedia | |
Mae paromomycin yn wrthfiotic a ddefnyddir i drin nifer o heintiau gan gynnwys amebiasis, giardiasis, leishmaniasis, a heintiau llyngyr rhuban.[1] Y fformiwla cemegol ar gyfer y cyffur hwn yw C₂₃H₄₅N₅O₁₄.
- ↑ Pubchem. "Paromomycin". pubchem.ncbi.nlm.nih.gov (yn Saesneg). Cyrchwyd 2018-02-28.
Previous Page Next Page
